Simcere Pharmaceutical Group, the Nanjing-based generic pharmaceutical maker, is relying on PR counsel and representation in the U.S. and China as it becomes the latest Chinese company to pull out of a U.S. stock listing.
Subscribe to O'Dwyer's website | Editorial
Contacts | Order
O'Dwyer Publications | Advertising Info | Contact O'Dwyer's | Terms and Conditions
Copyright © 1998-2016 J.R. O'Dwyer
271 Madison Ave., #600, New York, NY 10016; Tel: 212/679-2471 or Toll Free: